A new peer-reviewed study published in the Journal of Reconstructive Microsurgery is examining how preoperative use of GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy, Mounjaro, and Zepbound — may affect wound complications after free flap breast reconstruction surgery. The findings add to a growing but still unsettled body of research on how these medications interact with surgical outcomes.
Why Surgeons Are Paying Attention
GLP-1 receptor agonists are now widely prescribed for both type 2 diabetes and weight loss, meaning more patients than ever are arriving for surgery while on these medications. Free flap breast reconstruction is a complex procedure — typically performed after mastectomy — that involves transplanting tissue from one part of the body to rebuild the breast. Because the surgery is technically demanding and recovery lengthy, wound complications like infection or dehiscence (wound reopening) carry significant consequences.
The research question is timely: as GLP-1 use surges, surgical teams need clear guidance on whether patients should pause these medications before procedures and what risks, if any, they carry in the operating room and recovery room.
A Mixed Picture in the Research
The study's background section acknowledges the current uncertainty directly. According to the published abstract, some existing research suggests GLP-1 drugs may actually reduce certain surgical complications, including infection and wound dehiscence. However, other studies have reported increased risk in specific procedures. This study was designed specifically to evaluate whether preoperative GLP-1 use is associated with postoperative wound complications in free flap breast reconstruction patients.
The conflicting signals in prior research underscore why procedure-specific studies like this one matter — what holds true for one surgery type may not apply to another.
Key takeaway: The evidence on GLP-1 drugs and surgical wound outcomes is still evolving. If you are taking a GLP-1 medication and planning any surgery, speak with both your prescriber and your surgical team well in advance — do not stop or adjust your medication on your own.
What This Means for Patients on GLP-1 Medications
If you are currently taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) and have a surgery scheduled — particularly a reconstructive procedure — this research is relevant background to raise with your care team. Questions worth discussing include:
- Whether to pause your GLP-1 medication before surgery and for how long
- How your diabetes or weight management will be handled perioperatively if you do pause
- Whether your specific procedure has been studied in relation to GLP-1 use
- What wound monitoring protocols your surgical team follows
It is worth noting that major anesthesiology societies have issued guidance around GLP-1 use before procedures due to concerns about aspiration risk from delayed gastric emptying — a separate but related consideration your team will also want to weigh.
What to Watch Next
The full results and conclusions of this study were not available in the source material reviewed for this article. As the complete findings are published and reviewed by the broader medical community, updated guidance for surgeons and patients is likely to follow. Research in this area is accelerating alongside the rapid growth in GLP-1 prescriptions, and more procedure-specific data should emerge in the coming months and years.
Frequently Asked Questions
Surgical planning with a GLP-1 medication on board involves multiple considerations unique to each patient's health history and procedure. If you are taking Ozempic, Wegovy, Mounjaro, or Zepbound and have an upcoming surgery, speak with your prescriber and surgical team as early as possible to make an informed, personalized plan.
- PubMed, peer-reviewed journal article, 'GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction,' Journal of Reconstructive Microsurgery, date not specified in source material